Premium
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma
Author(s) -
de Souza Viana Luciano,
de Aguiar Silva Felipe Coelho,
Andrade dos Anjos Jacome Alexandre,
Calheiros Campelo Maia Danielle,
Duarte de Mattos Marcos,
Arthur Jacinto Alexandre,
Elias Mamere Augusto,
Boldrini Junior Domingos,
de Castro Capuzzo Renato,
Roberto Santos Carlos,
Lopes Carvalho Andre
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24137
Subject(s) - regimen , cisplatin , paclitaxel , medicine , oncology , induction chemotherapy , chemoradiotherapy , head and neck squamous cell carcinoma , basal cell , head and neck cancer , head and neck , chemotherapy , surgery , radiation therapy
Background The purpose of this phase II trial was to evaluate the tolerability, safety, and efficacy of a non–5‐fluorouracil (5‐FU)‐based induction chemotherapy followed by chemoradiotherapy (CRT) for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Methods Sixty patients with stage III to IV HNSCC were treated with induction paclitaxel and cisplatin (TP; paclitaxel 175 mg/m 2 and cisplatin 80 mg/m 2 , 3 cycles) followed by CRT (cisplatin 100 mg/m 2 ; D1, 22, and 43 of radiotherapy). Results Fifty‐six patients (93.3%) completed 3 cycles of induction TP (no treatment‐related deaths), 52 (86.7%) completed definitive CRT per protocol (adverse event [AE] grade ≥2 in 53.3%). The overall response rate after induction TP was 82.5% for patients with resectable disease and 55.5% for unresectable disease ( p = .023), and complete response (CR) rate after CRT was 70.0% for patients with resectable disease and 30.0% for unresectable disease ( p = .005). Conclusion Induction TP followed by cisplatin based‐CRT was well‐tolerated, safe, and had high overall response rate in selected patients with locally advanced HNSCC. © 2015 Wiley Periodicals, Inc. Head Neck 38 : E970–E980, 2016